Erlotinib

A cell-permeable inhibitor that binds ERK2 near its docking domain (KD = 5 &microM) blocks ERK-specific phosphorylation of Rsk-1 and TCF/Elk-1 but does not affect ERK1/2 phosphorylation by MEK1/2 completely prevents proliferation of several

Extracellular signal-regulated kinase 1 (ERK1) belongs to mitogen-activated protein kinases (MAPK)/ERK family of intermediate proteins in the signaling pathways. This gene contains nine exons and eight introns, and spans 9kb.

Anti-ERK 1 (RABBIT) antibody is suitable for use in ELISA and Western Blotting. Specific conditions of reactivity should be optimized by the end user. Expect a band of approximately 43 kDa.

ERK1/2 inhibitor 1 is a potent, orally bioavailable ERK1 / 2 inhibitor, showing 60% inhibition at 1 nM and an IC 50 of 3.0 nM against ERK1 and ERK2 , respectivelyIn VitroERK1/2 inhibitor 1 (Compound 27) shows excellent antiproliferative potency with

Biochem/physiol Actions ERK2 is a protein serine/threonine kinase that is a member of the extracellular signal-regulated kinases (ERKs) which are activated in response to numerous growth factors and cytokines. Activation of ERK2 requires both

Biochem/physiol Actions Erlotinib is an orally available, potent, and specific inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase. Erlotinib binds to the ATP binding site of the receptor.

Biochem/physiol Actions Erlotinib is an orally available, potent, and specific inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase. Erlotinib binds to the ATP binding site of the receptor.

A tyrosine kinase inhibitor which acts on EGFR, inhibiting EGFR-associated kinase activity (IC50 = 2.5 &microM) and tumor growth in human HN5 tumor xenografts in mice with an ED50 value of 9 mg/kg drug form of Erlotinib, Tarceva&trade, is used to

A tyrosine kinase inhibitor which acts on EGFR, inhibiting EGFR-associated kinase activity (IC50 = 2.5 &microM) and tumor growth in human HN5 tumor xenografts in mice with an ED50 value of 9 mg/kg drug form of Erlotinib, Tarceva&trade, is used to

A tyrosine kinase inhibitor which acts on EGFR, inhibiting EGFR-associated kinase activity (IC50 = 2.5 &microM) and tumor growth in human HN5 tumor xenografts in mice with an ED50 value of 9 mg/kg drug form of Erlotinib, Tarceva&trade, is used to

A tyrosine kinase inhibitor which acts on EGFR, inhibiting EGFR-associated kinase activity (IC50 = 2.5 &microM) and tumor growth in human HN5 tumor xenografts in mice with an ED50 value of 9 mg/kg drug form of Erlotinib, Tarceva&trade, is used to

An isothiocyanate derived from cruciferous vegetables that has significant antiapoptotic and antioxidant effects in various cancer cells.